Open main menu

Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz.[1]

Ertapenem
Ertapenem Formula V.1.svg
Clinical data
Trade namesInvanz
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B3
  • US: B (No risk in non-human studies)
Routes of
administration
Intramuscular, intravenous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability90% (intramuscular)
Protein bindingInversely proportional to concentration; 85 to 95%
MetabolismMinor hydrolysis of beta-lactam ring, CYP not involved
Elimination half-life4 hours
ExcretionRenal (80%) and fecal (10%)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H25N3O7S
Molar mass475.516 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

ReferencesEdit

  1. ^ Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (November 2011). "Carbapenems: past, present, and future". Antimicrob. Agents Chemother. 55 (11): 4943–60. doi:10.1128/AAC.00296-11. PMC 3195018. PMID 21859938.